- Home
- VNO vs COGT Comparison
VNO vs COGT Comparison
Compare VNO & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | COGT |
|---|---|---|
| Founded | 1946 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | VNO | COGT |
|---|---|---|
| Price | $33.75 | $39.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $37.50 | $30.17 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 02-09-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $1,903,939,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.18 | N/A |
| P/E Ratio | $8.01 | ★ N/A |
| Revenue Growth | ★ 1.75 | N/A |
| 52 Week Low | $29.68 | $3.72 |
| 52 Week High | $45.37 | $43.73 |
Technical Indicators
Market Signals| Indicator | VNO | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 60.74 |
| Support Level | $33.23 | $33.84 |
| Resistance Level | $34.62 | $36.88 |
| Average True Range (ATR) | 0.83 | 1.93 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 44.85 | 75.53 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.